FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Backed By Two Drug Powerhouses, GenSight Alum Launches New Biotech With $40 Million May 3, 2017 Booming Drug Sales Make This San Diego Biotech a Prime M&A Target November 2, 2017 Booming Visterra Outgrows Kendall Square Space, Heads to Suburbs February 5, 2018
